|
TADA2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.13495887635418E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
9.14469999724332E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
5.845600E-01 |
| Stage1-vs-Stage3 |
3.854200E-02 |
| Stage1-vs-Stage4 |
2.566500E-04 |
| Stage2-vs-Stage3 |
6.507800E-02 |
| Stage2-vs-Stage4 |
5.035700E-03 |
| Stage3-vs-Stage4 |
1.921650E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.15574216863479E-13 |
| Normal-vs-AfricanAmerican |
8.45919999999944E-05 |
| Normal-vs-Asian |
2.42680320283739E-11 |
| Caucasian-vs-AfricanAmerican |
7.173600E-02 |
| Caucasian-vs-Asian |
9.005800E-01 |
| AfricanAmerican-vs-Asian |
1.560150E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.27453603226968E-13 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.682800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.7245983247326E-12 |
| Normal-vs-Age(81-100Yrs) |
2.176500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.423600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.119000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.602600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.113000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.481400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.888600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.89519999999055E-05 |
| Classical-VS-Follicular |
6.436200E-01 |
| Classical-VS-Other |
6.760200E-01 |
| Classical-VS-Normal |
8.49298409377752E-12 |
| Tall-VS-Follicular |
1.620940E-04 |
| Tall-VS-Other |
1.157030E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
6.354800E-01 |
| Follicular-VS-Normal |
2.03030037226881E-10 |
| Other-VS-Normal |
9.352700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
9.32587340685131E-15 |
| N0-vs-N1 |
1.785620E-02 |
|
|
